Wow. The 1c raise over at OncoSil from the (already low) 3.1c...

Wow. The 1c raise over at OncoSil from the (already low) 3.1c opening price yesterday is simply insane. I just spotted OSL in the HC biggest losers list from yesterday and after reading your comment @kiwig and their thread you’ve really got to wonder what on earth Otto (chairman of both) is up to with these biotechs. That raise discount yesterday has decimated the portfolio value of existing OSL holders!

RHY’s $8.8m cash balance at the end of the last quarter will really need to last the distance - when you exclude the one-off $2.7m Govt grant/tax incentive disclosed in the 4C to 31 December, RHY burned through ~$2.4m last quarter in R&D and admin. It’s now nearly one quarter later too as end of March is soon upon us. I can’t see costs here becoming any less if it’s now back to the drawing board with a future resubmission to TGA and all the prior work this likely entails. More transparency and clarity from management on next steps is now becoming quite critical imo.